Bogomiakova M E, Eremeev A V, Lagarkova M A
Federal Research and Clinical Center of Physical-Chemical Medicine, Federal Medical Biological Agency, Moscow, 119435 Russia.
Immunology Department, Biological Faculty, Moscow State University, Moscow, 119234 Russia.
Mol Biol (Mosk). 2019 Sep-Oct;53(5):725-740. doi: 10.1134/S0026898419050045.
Human pluripotent stem cells, which include embryonic stem cells and induced pluripotent cells (iPSCs), are capable of unlimited division and differentiation into all cells of the body. These cells are considered as a potential source of various types of cells for transplantations. The use of autologous iPSCs is not potentially associated with immune rejection and does not require immunosuppression required for allogeneic grafts. However, the high cost of this technology and the duration of obtaining iPSCs and differentiated cells may limit the use of autologous iPSCs in clinical practice. In addition, full equivalence and immunological compatibility of autologous iPSCs and their derivatives have been repeatedly questioned. One approach to solving the problem of the immunological compatibility of allogeneic derivatives of iPSCs can be the establishment of cell lines with reduced immunogenicity. Differentiated derivatives of such iPSCs may be suitable for transplantation to any patient. This review discusses the strategies for evading immune surveillance in normal and tumor processes that can be used to establish stem cell lines with reduced immunogenicity.
人类多能干细胞,包括胚胎干细胞和诱导多能干细胞(iPSC),能够无限分裂并分化为体内所有细胞。这些细胞被认为是用于移植的各种类型细胞的潜在来源。使用自体iPSC不会潜在地引发免疫排斥,也不需要同种异体移植物所需的免疫抑制。然而,这项技术的高成本以及获取iPSC和分化细胞的时间可能会限制自体iPSC在临床实践中的应用。此外,自体iPSC及其衍生物的完全等效性和免疫相容性也屡屡受到质疑。解决iPSC同种异体衍生物免疫相容性问题的一种方法是建立免疫原性降低的细胞系。这种iPSC的分化衍生物可能适用于移植给任何患者。本综述讨论了在正常和肿瘤过程中规避免疫监视的策略,这些策略可用于建立免疫原性降低的干细胞系。